|
|
|
Stem Cell Related Patent Number US6372262
| Title: | Serum-derived factor inducing cell differentiation and medical uses thereof | | Inventors: | Peled, Tony; Mevaseret, Israel
Fibach, Eitan; Mevaseret Zion, Israel
Rachmilewitz, Eliezer A.; Jerusalem, Israel | | Summary: | Described herein is a serum-derived factor with low molecular weight, methods and uses thereof. The invention relates to a biologically active serum-derived composition (SDF), characterized by a low molecular weight and by being electrically charged at acidic pH while having absorption at 280 nm. Properties of the SDF and its complex with ceruloplasmin (CP) are provided, along with methods by which the molecular weight of the SDF was determined from electron spray mass spectrometry. The SDF or its complex with CP are described as being capable of inducing terminal cell differentiation of leukemic cells, thereby causing the cells to lose their ability to proliferate and their ability for self cell renewal. Other properties of the SDF or the complex with CP include the capacity for stimulating the proliferation and enhancement of early, normal progenitor cells and inhibiting enhanced angiogenesis. Therapeutic applications include inducing terminal cell differentiation in leukemic cells, inducing the remission of tumors, expanding hematopoietic normal stem and progenitor bone marrow transplants, and inhibiting angiogenesis. | | Abstract: | The present invention relates to a biologically active serum-derived composition of matter (SDF), having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm. The molecular weight of said SDF was determined by electron spray mass spectrometry and is of 316 Da. SDF of the present invention or its complex with ceruloplasmin (CP) have several therapeutic properties. For example, SDF or its complex with CP is capable of inducing terminal cell differentiation of leukemic cells, which as a result, may lose their ability to proliferate and their ability for self cell renewal. Further, SDF or the complex with CP is capable of stimulating the proliferation of early, normal progenitor cells and inhibiting enhanced angiogenesis. In addition, SDF or its complex with CP is capable of ex vivo expanding normal stem and progenitor cells. The invention also relates to pharmaceutical composition comprising as active ingredient SDF or its complex and optionally further comprising pharmaceutically acceptable additives. Such pharmaceutical compositions may be for inhibiting enhanced angiogenesis, for inducing remission of tumors, for maintaining tumor remission, and for expanding hematopoietic normal stem and progenitor bone marrow transplants. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6372262 | | Application Number: | US1999000332254 | | Date Filed: | 08/06/1999 | | Date Published: | 16/04/2002 | | Assignee: | Hadasit Medical Research Services and Development Ltd., Jerusalem, Israel |
|
|
